Journal of psychiatric research

Methods and approaches in psilocybin therapy for depression: A systematic review

Updated

Abstract

A total of 28 psychotherapy protocols for psilocybin-assisted psychotherapy (PAP) were reviewed.

  • All reviewed protocols included preparatory and integration sessions surrounding the psychedelic dosing session.
  • Considerable variability was found in aspects such as the duration and number of therapy sessions.
  • Inconsistencies in the therapeutic models used were noted across the different protocols.
  • Limitations were identified due to a lack of clarity in describing therapeutic approaches.
  • No validated or universally agreed upon protocol for PAP currently exists.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest Dr. Joshua D Rosenblat has received research grant support from the Canadian Institute of Health Research (CIHR), Physician Services Inc (PSI) Foundation, Labatt Brain Health Network, Brain and Cognition DiscoveryFoundation (BCDF), Canadian Cancer Society, Canadian Psychiatric Association, Academic Scholars Award, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M. West Family Memorial Fund and Timeposters Fellowship and industry funding for speaker/consultation/research fees from iGan, Boehringer Ingelheim, Janssen, Allergan, Lundbeck, Sunovion and COMPASS. He was formerly the Chief Medical and Scientific Officer of Braxia Scientific and the medical director of the Canadian Rapid Treatment Centre of Excellence (Braxia Health). Dr. Roger McIntyre has received research grant support from Global Alliance for Chronic Diseases/Canadian Institutes of Health Research (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Zoe Doyle is a Clinical Project Lead at Braxia Scientific and a Project Lead at Braxia Health (Canadian Rapid Treatment Centre of Excellence). None of the remaining authors have any potential competing interests to disclose.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free